NOVOCURE LTD (NVCR) Stock News

USA - NASDAQ:NVCR - JE00BYSS4X48 - Common Stock

14.66 USD

+0.61 (+4.34%)

Last: 10/3/2025, 8:00:02 PM

14.7 USD

+0.04 (+0.27%)

After Hours: 10/3/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NVCR Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Novocure

Novocure to Report Third Quarter 2025 Financial Results

5 days ago - By: Novocure

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

19 days ago - By: Novocure

Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

a month ago - By: The Motley Fool - Mentions: VKTX LLY NVO

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts

2 months ago - By: Benzinga - Mentions: MOH HCA

Top 3 Health Care Stocks That May Explode In July

2 months ago - By: The Motley Fool

Novocure: Steady Ahead of Key Milestones

a month ago - By: Novocure

Novocure Announces Upcoming Investor Events

a month ago - By: Novocure

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

a month ago - By: Zacks Investment Research - Mentions: LMAT EHC NVST

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer

2 months ago - By: Novocure

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

2 months ago - By: Yahoo Finance

Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR)

2 months ago - By: Benzinga

NovoCure Earnings Preview

2 months ago - By: Novocure

Novocure Reports Second Quarter 2025 Financial Results

3 months ago - By: Novocure

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

3 months ago - By: Novocure

Novocure to Report Second Quarter 2025 Financial Results

4 months ago - By: Yahoo Finance - Mentions: SHOP WFC NVDA S ...

Why Shopify Stock Popped Today

4 months ago - By: Zacks Investment Research - Mentions: ANGO CVS ITGR

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

4 months ago - By: Novocure

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

4 months ago - By: Yahoo Finance - Mentions: AMZN CP UBER GOOG ...

Billionaire Investor Bill Ackman Just Sold This Railway Stock 'With Regret' So He Could Buy the Dip on a Mag Seven Stock At a "Uniquely Attractive Time"

4 months ago - By: Yahoo Finance - Mentions: TSCO BKH D LDOS ...

1 Excellent Dividend Stock to Buy Right Now

4 months ago - By: Novocure

Novocure Announces Upcoming Investor Events

5 months ago - By: Yahoo Finance - Mentions: CAVA TSHA TTWO AMAT ...

Cava: Rapid Growth but Some Concerns

5 months ago - By: Zacks Investment Research

Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?

5 months ago - By: Zacks Investment Research

Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?

5 months ago - By: Yahoo Finance - Mentions: T VZ DHI CMG ...

Why NovoCure Stock Skyrocketed This Week

5 months ago - By: Yahoo Finance

Why NovoCure Stock Leaped 4% Higher Today

5 months ago - By: Zacks Investment Research

NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates